Intelligence · Patent portfolio
Vertex Pharmaceuticals (Australia) Patents
Full USPTO pharma patent portfolio for Vertex Pharmaceuticals (Australia) — grant dates, expiration, and drug cross-links.
- Patents
- 991
- Expiring ≤24m
- 63
Quick answer
Vertex Pharmaceuticals (Australia) has 991 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 63 expire within 24 months — use filters for patent-cliff planning.
-
US 8993600
Modulators of ATP-binding cassette transporters
granted -
US 8987454
Azaindoles useful as inhibitors of JAK and other protein kinases
granted -
US 8969574
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
granted -
US 8969356
Compounds useful as inhibitors of ATR kinase
granted -
US 8969382
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 8969359
Gyrase and topoisomerase IV inhibitors
granted -
US 8969360
Compounds useful as inhibitors of ATR kinase
granted -
US 8969386
Modulators of CFTR
granted -
US 8962856
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 8962642
5-cyano-4- (pyrrolo [2,3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
granted -
US 8962631
Compounds useful as inhibitors of ATR kinase
granted -
US 8957078
Compounds useful as inhibitors of ATR kinase
granted -
US 8952050
Modulators of ATP-binding cassette transporters
granted -
US 8952049
Modulators of ATP-binding cassette transporters
granted -
US 8946425
Processes and intermediates for producing azaindoles
granted -
US 8937064
Pyrazolo[1,5-a]pyrimidines useful as JAK2 inhibitors
granted -
US 8921376
Pyrrolopyridines useful as inhibitors of protein kinase
granted -
US 8916565
Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
granted -
US 8916538
Solid forms of a thiophosphoramidate nucleotide prodrug
granted -
US 8912199
Modulators of ATP-binding cassette transporters
granted -
US 8912198
Compounds useful as inhibitors of ATR kinase
granted -
US 8912326
Process of making gyrase and topoisomerase inhibitors
granted -
US 8895723
Methods of preparing substituted nucleotide analogs
granted -
US 8895740
Pyrazolopyrazine kinase inhibitors
granted -
US 8889875
Pyridyl derivatives as CFTR modulators
granted -
US 8883206
Pharmaceutical composition and administrations thereof
granted -
US 8884018
Process for preparing modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 8883781
Thienopyrimidines useful as modulators of ion channels
granted -
US 8883766
Ion channel modulators and methods of use
granted -
US 8877759
Aminopyrazines as ATR kinase inhibitors
granted -
US 8871904
Processes and intermediates
granted -
US 8871774
Inhibitors of influenza viruses replication
granted -
US 8865751
Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
granted -
US 8865771
Amides useful as inhibitors of voltage-gated sodium channels
granted -
US 8853244
Thiophene-carboxamides useful as inhibitors of protein kinases
granted -
US 8853152
Pharmaceutical compositions
granted -
US 8853415
Modulators of ATP-binding cassette transporters
granted -
US 8853217
Compounds useful as inhibitors of ATR kinase
granted -
US 8853254
Modulators of ATP-binding cassette transporters
granted -
US 8846686
Compounds useful as inhibitors of ATR kinase
granted -
US 8846918
Compounds useful as inhibitors of ATR kinase
granted -
US 8846718
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxo1-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
granted -
US 8846753
Modulators of ATP-binding cassette transporters
granted -
US 8846917
Compounds useful as inhibitors of ATR kinase
granted -
US 8846896
Methods of preparing substituted nucleotide analogs
granted -
US 8841449
Compounds useful as inhibitors of ATR kinase
granted -
US 8841483
Compositions useful as inhibitors of voltage-gated sodium channels
granted -
US 8841282
Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels
granted
Frequently asked questions
How many patents does Vertex Pharmaceuticals (Australia) have?
991 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Vertex Pharmaceuticals (Australia) patents expire?
63 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory